Literature DB >> 28661018

Clinical characterization of dystonia in adult patients with Huntington's disease.

N A van de Zande1,2, T H Massey1,3, D McLauchlan1, A Pryce Roberts3, R Zutt4, M Wardle5,6, G C Payne5, C Clenaghan1, M A J Tijssen4, A E Rosser1,6,7, K J Peall1,3,6.   

Abstract

BACKGROUND AND
PURPOSE: Huntington's disease (HD) is an autosomal dominant, neurodegenerative movement disorder, typically characterized by chorea. Dystonia is also recognized as part of the HD motor phenotype, although little work detailing its prevalence, distribution, severity and impact on functional capacity has been published to date.
METHODS: Patients (>18 years of age) were recruited from the Cardiff (UK) HD clinic, each undergoing a standardized videotaped clinical examination and series of functional assessment questionnaires (Unified Huntington's Disease Rating Scale, Burke-Fahn-Marsden Dystonia Rating Scale and modified version of the Toronto Western Spasmodic Torticollis Rating Scale). The presence and severity of dystonia were scored by four independent neurologists using the Burke-Fahn-Marsden Dystonia Rating Scale and Unified Huntington's Disease Rating Scale. Statistical analysis included Fisher's exact test, Wilcoxon test, anova and calculation of correlation coefficients where appropriate.
RESULTS: Forty-eight patients [91% (48/53)] demonstrated evidence of dystonia, with the highest prevalence in the left upper limb (n = 44, 83%), right upper limb most severely affected and eyes least affected. Statistically significant positive correlations (P < 0.05) were observed between dystonia severity and increasing HD disease stage and motor disease duration. Deterioration in functional capacity also correlated with increasing dystonia severity. No significant relationship was observed with age at motor symptom onset or CAG repeat length.
CONCLUSIONS: We report a high prevalence of dystonia in adult patients with HD, with worsening dystonia severity with increasing HD disease stage and motor disease duration. The recognition and management of dystonic symptoms in routine clinical practice will aid overall symptomatic treatment and functional improvement.
© 2017 EAN.

Entities:  

Keywords:  Huntington's disease; dystonia; movement disorders; quality of life; scales

Mesh:

Substances:

Year:  2017        PMID: 28661018     DOI: 10.1111/ene.13349

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

Review 2.  Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review.

Authors:  Hannah S Bakels; Raymund A C Roos; Willeke M C van Roon-Mom; Susanne T de Bot
Journal:  Mov Disord       Date:  2021-10-12       Impact factor: 9.698

3.  Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease.

Authors:  Jingyu Liu; Jennifer Ciarochi; Vince D Calhoun; Jane S Paulsen; H Jeremy Bockholt; Hans J Johnson; Jeffrey D Long; Dongdong Lin; Flor A Espinoza; Maria B Misiura; Arvind Caprihan; Jessica A Turner
Journal:  Front Neurol       Date:  2018-03-29       Impact factor: 4.003

4.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

Review 5.  Classification of Dystonia.

Authors:  Lazzaro di Biase; Alessandro Di Santo; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Vincenzo Di Lazzaro
Journal:  Life (Basel)       Date:  2022-01-29

6.  Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokinetic-rigid motor subtypes in Huntington's disease.

Authors:  Jannis Achenbach; Sarah Maria von Hein; Carsten Saft
Journal:  Brain Behav       Date:  2020-06-12       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.